We have assessed metabolic and immunological effects of a nelfinavir-containing regimen in healthy HIV-1-uninfected individuals receiving post-exposure prophylaxis. Our data suggest that this regimen is well tolerated and did not modify the lipid or hepatic profiles. This antiretroviral regimen seems to have no effect on lymphocyte T cell subsets, however, it could have an immune-modulator role, inducing an increase in the proliferative responses to mitogens.
References
1.
PlanaM., GarciaF., GallartM.T., MiroJ.M., & GatellJ.M.Lack of T-cell proliferative response to HIV-1 antigens after one year of HAART in very early HIV-1 disease. Lancet1998; 352: 1194–1195.
2.
ParkinJ.M., MurphyM., AndersonJ., El GadiS., ForsterG., & PinchingA.J.Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet2000; 355: 722–723.
3.
Centers for Disease Control and Prevention.Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures. World-wide 1997-2000. MMWR Morbidity and Mortality Weekly Report2001; 49: 1153–1156.
4.
Italian Registry of Antiretoviral post-exposure prophylaxis.Effect of short-course of antiretroviral agents on serum triglycerides of healthy individuals. AIDS2000; 14: 2407–2408.
5.
PurnellJ.Q., ZambonA., KnoppR.H., PizzutiD.J., AchariR., LeonardJ.M., LockeC., & BrunzellJ.D.Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS2000; 14: 51–57.
6.
PuroV., & IppolitoG.Effect of antiretroviral agents on T-lyphocyte subset counts in healthy HIV-negative individuals. Journal of Acquired Immune Deficiency Syndromes2000; 24: 440–443.
7.
MilazzoL., VairaL.M., & CremoniL.CD4 lymphocyte count variations in HIV-negative subjects treated with zidovudine. AIDS1996; 10: 1444–1445.
8.
de MartinoM., GalliL., ChiarelliF., RossiM.E., & VierucciA.Do nucleoside analogues directly influence T lymphocyte subset counts? The pediatric model. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1998; 18: 391–393.
9.
BarkerE., KahnJ., FujimuraS., & LevyJ.A.Protease inhibitors do not increase the CD4+ cell count in HIV-uninfected individuals. AIDS1998; 12: 1117–1118.
10.
WeicholdF.F., BryantJ.L., PatiS., BarabitskayaO., GalloR.C., & ReitzM.S.HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. Journal of Human Virology1999; 2: 261–269.
11.
SloandE., KumarP.N., ChaudhuriA., WeicholdF.F., & YoungN.S.Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo.Blood1999; 94: 1021–1027.
12.
PhenixB.N., LumJ.J., NieZ., Sanchez-DardonJ., & BadleyA.D.Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood2001; 98: 1078–1085.
13.
LevyJ.A., RamachandranB., BarkerE., GuthrieJ., ElbeikT., & CoffinJ.M.Plasma viral load, CD4+ cell counts, and HIV-1 production by cells. Science1996; 271: 670–671.
14.
AutranB., CarcelainG., LiT.S., BlancC., MathezD., TubianaR., KatlamaC., DebreP., & LeibowitchJ.Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science1997; 277: 112–116.
15.
PlanaM., GarcíaF., GallartM.T., TortajadaC., SorianoA., PalouE., MalenoM.J., BarceloJ.J., VidalC., CrucetaA., MiroJ.M., & GatellJ.M.Immunological benefits of antiretroviral therapy in very early stages of asymtomatic chronic HIV-1 infection. AIDS2000; 14: 1921–1933.
